ArcherDx forms NGS partnership, 7/16

Create PDF

July 2016—

Under terms of an agreement with Illumina, ArcherDx will lead the development of a series of diagnostic tests, using ArcherDx’s Anchored Multiplex PCR chemistry, that will run on the Illumina MiSeqDx instrument. This agreement reflects the commitment of both companies to provide NGS-based diagnostics to support current and future clinical trials.

ArcherDx, 303-357-9001